Marker Therapeutics Inc (MRKR) Stock Price, Quote & News

Company Profile

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND...

Industry: Biotechnology

Sector: Healthcare

Phone: 713 400 6400

Website: markertherapeutics.com

Address:

2450 Holcombe Blvd, MS: BCM251, Houston, United States

WhereAmIGoing Aug. 7 at 3:14 PM

$MRKR

0 · Reply

moneygrabber55 Aug. 7 at 12:42 AM

$MRKR can this see $2 again?

1 · Reply

WhereAmIGoing Aug. 6 at 8:53 PM

$MRKR 😝 how pathetic are you though?

0 · Reply

SimSimBola Aug. 6 at 7:38 PM

$MRKR you have no shame? you are a retail buyer, wishing upon a stock. you have no leverage.zero, none. And you showcase this by crying to the company when the stock falls below a margin you have determined to be too low. Pathetic! 👇🏽

0 · Reply

dwaslimit1 Aug. 6 at 6:56 PM

$MRKR I tried to use their investor relations link on the website to reach Juan directly but I have not received a response nor do I expect to. You are a man of great influence so perhaps you can dig your heels in a bit and help steer this company in the right direction. As an investor in many biotechs, I have never seen such a large value dislocation between the market cap of a company, and the potential they embody. It is my belief that hiring a new CEO, who has pharmaceutical sales experience from a reputable company, and who can properly navigate the business side of things, would be indelible to Marker. I would appreciate it if you could email me back to brainstorm strategies to increase the visibility of Marker or at least to address my concerns of what I am saying. Thank you, Daniel

0 · Reply

dwaslimit1 Aug. 6 at 6:56 PM

$MRKR please see my email to Steven Elms, who is on the Marker Board of Directors and is a managing partner at Aisling. Hi Steven, I am a current shareholder of Marker Therapeutics. I am reaching out to you because you are a board member and I have concerns about the governance of the company.We both know that Marker possesses a very unique technology. Their recent data is quite intriguing to solidify this view. However, its present valuation would make one think otherwise. I have concerns that Juan Vera does not know / lacks the business savviness to run this company. He is a science guy but without the proper marketing, sales, and business expertise, I fear this company will never get off the ground. You may think it's inappropriate that I am reaching out but I have no other recourse. I am not even able to reach anyone at Marker.

0 · Reply

DaSqueeza Aug. 6 at 1:41 PM

$MRKR

1 · Reply

Viperwilder Aug. 5 at 4:28 PM

$MRKR I think if you want to buy this, now is the time

0 · Reply

WhereAmIGoing Aug. 5 at 4:21 PM

$MRKR

0 · Reply

moneygrabber55 Aug. 5 at 12:14 PM

$MRKR I will keep buying!!!

0 · Reply

Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

Jun 17, 2025, 8:00 AM EDT - 7 weeks ago

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

May 20, 2025, 8:00 AM EDT - 2 months ago

Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

May 19, 2025, 8:00 AM EDT - 2 months ago

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

Apr 1, 2025, 8:00 AM EDT - 4 months ago

Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference

Mar 31, 2025, 8:45 AM EDT - 4 months ago

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

Feb 25, 2025, 7:00 AM EST - 5 months ago

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Dec 19, 2024, 8:06 AM EST - 8 months ago

Marker Therapeutics Announces $16.1 Million Private Placement

Dec 19, 2024, 8:05 AM EST - 8 months ago

Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma

Dec 17, 2024, 7:00 AM EST - 8 months ago

Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer

Dec 10, 2024, 8:30 AM EST - 8 months ago

Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium

Nov 26, 2024, 11:00 AM EST - 9 months ago

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

Nov 14, 2024, 4:30 PM EST - 9 months ago

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma

May 15, 2024, 4:15 PM EDT - 1 year ago

Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Apr 8, 2024, 7:00 AM EDT - 1 year ago

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies

Mar 25, 2024, 5:45 PM EDT - 1 year ago

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

Mar 22, 2024, 12:30 PM EDT - 1 year ago

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Jan 22, 2024, 7:30 AM EST - 1 year ago

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

Jan 8, 2024, 8:24 AM EST - 1 year ago

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

Dec 21, 2023, 11:00 AM EST - 1 year ago

Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”

Nov 9, 2023, 5:00 PM EST - 1 year ago

Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Sep 11, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 17, 2023, 9:03 AM EDT - 2 years ago

Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies

Aug 14, 2023, 4:30 PM EDT - 2 years ago

Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 7, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program

Jul 10, 2023, 7:00 AM EDT - 2 years ago

European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients

Jun 26, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration

Jun 12, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial

May 31, 2023, 6:30 AM EDT - 2 years ago

Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells

May 8, 2023, 7:30 AM EDT - 2 years ago

Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer

May 1, 2023, 7:30 AM EDT - 2 years ago

Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™

Mar 22, 2023, 8:10 AM EDT - 2 years ago

Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results

Dec 13, 2022, 7:00 AM EST - 2 years ago

Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million

Sep 13, 2022, 7:00 AM EDT - 3 years ago

Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker's Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML

Sep 8, 2022, 7:00 AM EDT - 3 years ago

Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference

Aug 11, 2022, 4:22 PM EDT - 3 years ago

Marker Therapeutics Reports Q2 2022 Operating and Financial Results

$Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma$